Leman
Latest round
- Series A
Last raised
- Mar 2026
Total raised
- $37M
Investors
- 9
About Leman
, trading as Leman, operates as a drug developer, focusing on immunometabolism reprogramming and artificial intelligence for novel tumor immunotherapy. The company's founding team is from the Swiss federal Institute of Technology in Lausanne. Leman is reaching a strategic cooperation with XtalPi Inc. It is headquartered in Shenzhen and has a clinical center in Switzerland. The company focuses on the development, production and commercialization of novel oncology immunotherapeutic drugs and has developed the Meta 10 immunometabolism reprogramming technology. The company develops novel metabolically enhanced tumor immunotherapy that can reverse immune cell depletion and induce stem immune memory, enabling the reactivation of terminally depleted T cells. The platforms established by the company are involved in the discovery, development and production of biomolecular drugs and novel immune cellular drugs, metabolically enhanced immune cell therapy and artificial intelligence (AI) computing-based super immunomodulator research and development. The company generates revenue by providing immuno-oncology drugs and services..
Who invested in Leman
9 investors across 4 rounds
See all investors in Leman
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Leman
Who invested in Leman?
Leman has 9 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Leman raised?
Leman has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Leman last raise money?
Leman's most recent round on record is a Series A, in Mar 2026.
What does Leman do?
, trading as Leman, operates as a drug developer, focusing on immunometabolism reprogramming and artificial intelligence for novel tumor immunotherapy.
Where is Leman headquartered?
Leman is headquartered in Shenzhen, China.
Which VCs invest in companies like Leman?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Leman's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Leman? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.